BCL2L1 and cancer: Another PROTAC recruiting Inhibitors of Apoptosis proteins (IAP) also achieved BCL-xL degradation in cancer cell lines opening the avenue of selective BCL-xL degraders based on specific cellular E3 ligase activities [64].